iBio (IBIO) Stock: The Fun Is Far From Over

iBio Inc (NYSEAMERICAN: IBIO) had a great day in the market a couple of sessions ago, climbing to highs that we haven’t seen since 2016. So, naturally, we saw a bit of profit taking yesterday. Nonetheless, the stock is back up this morning, trading on gains of more than 8%, and I’m here to tell you, the fun is far from over.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

IBIO Stock Has The Potential To Gain In Multiples

Since I started following iBio, I’ve been incredibly bullish, and it worked out. The stock has climbed from around $0.30 per share to well over $5 per share, and continues to be the darling of StockTwits.

While we have seen a tremendous run in the value of the stock over the past few months, I believe that there is still room for the stock to gain in multiples from here. That’s especially the case as soon as news with regard to the company’s vaccine candidates is released.

For those of you who haven’t been following, IBIO has been a key player in the global race to develop a vaccine for SARS-CoV-2, the novel coronavirus that leads to COVID-19. With the pandemic changing our way of life, a vaccine has never been in such high demand.

So, what has IBIO done in the vaccine space?

The company has partnered with a Chinese firm known as CC-Pharming, announced two coronavirus vaccine development programs, and built and maintains the FastPharming Facility (allbeit quite a while ago). All of these events have significant implications when it comes to the race to develop and commercialize a vaccine.

  • CC-Pharming – The partnership with CC-Pharming has two key benefits. First and foremost, CC-Pharming is Chinese, opening the door to mainland China, where the coronavirus started and the second largest economy in the world. Moreover, CC-Pharming has already developed a vaccine for a sister virus to the novel coronavirus. That experience is invaluable when working to quickly develop vaccines.
  • Multiple Development Programs – We all know that if you have two chances to do something new, you have far more potential than if you only have one chance. With IBIO having two vaccine development programs, it has more of a chance of hitting the nail on the head with at least one of them.
  • FastPharming Facility – Years ago, the United States government teamed up with IBIO to develop the FastPharming Facility. However, the Facility has never been more relevant than today. After all, it was built to manufacture vaccines and other biologic agents quickly in the face of a pandemic. This gives the company a manufacturing competitive advantage, being able to produce faster than any other source.

Massive Gains Likely Ahead

It has been quite a while since we’ve heard anything from iBio about their vaccine development programs. About a couple of months, and investors are getting ancy. However, the move following the news is going to be worth the wait.

Should IBIO release any news that’s positive surrounding its work in the development of a coronavirus vaccine, it will likely lead to tremendous excitement among investors, leading the stock on a dramatic run for the top. Should the news be substantial, the stock could gain in multiples.

With a pretty long time passed since the last update, IBIO is likely strategizing and working to put news together. So, this catalystic event is likely to take place pretty soon.

The Bottom Line

The bottom line is that while Moderna, Inovio, and Pfizer are taking the limelight in the media, iBio is a vaccine play that should not be ignored. The company has several strategic advantages, and the value of these is still discounted in the market in my opinion. With news likely on the horizon, you should pay close attention to IBIO stock.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.